Theriva Gets Positive EMA Advice for VCN-01 Phase 3 Trial
Theriva’s Phase 2b VIRAGE trial in first-line metastatic pancreatic ductal adenocarcinoma (PDAC) reported improvements in overall survival, progression-free survival,...
Breakthrough Trial Offers New Hope for Stargardt Disease
Tinlarebant reduced the growth rate of Stargardt lesions by 35.7% versus placebo over 24 months in the Phase 3...
New Data: Leqembi’s Expanding Benefit for Early Alzheimer’s
Modeled long-term analyses from the Clarity AD open-label extension estimated that continuous lecanemab could delay progression from mild cognitive...
New Hope for APL: Quetzal Starts Phase III QTX-2101 Trial
Quetzal Therapeutics has opened a global, randomized Phase III trial of QTX-2101, an oral arsenic trioxide capsule, in newly...
Kymera to Announce KT-621 Atopic Dermatitis Trial Results
In a Phase 1 study in healthy volunteers, Kymera’s oral STAT6 degrader KT-621 achieved complete STAT6 degradation in blood...
New Hope in NSCLC: Enozertinib’s Powerful CNS Activity
Topline data from ORIC’s Phase 1b study of enozertinib (ORIC-114) in EGFR exon 20–mutated NSCLC show a 67% best...
Parkinson’s Trial: Solengepras Shows Remarkable Results
Solengepras reduced average daily OFF time by 1.3 hours versus placebo after 27 days (p=0.02) in a randomized Phase...
Apeiron Presents First-in-Human Data for GTA182 in NSCLC
Topline readout: In an ongoing Phase 1 study of GTA182 in MTAP-deleted solid tumors, the objective response rate was...
Bioversys Launches Promising Phase 3 Trial for BV100 Drug
In a Phase 2 study in ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii, BV100 delivered a 50% relative...
Study Assesses Emrosi™ (DFD-29) Impact on Microbial Flora
In a 60-subject, randomized, double-blind, placebo-controlled Phase 1 study, 16 weeks of low-dose oral minocycline (Emrosi, 40 mg modified-release;...